Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032
Summary
Seasonal influenza (SI) is a contagious respiratory viral illness. There are four types of SI viruses: A, B, C, and D; however, only types A and B cause human disease of public health concern (WHO, 2023). Influenza transmission occurs when people with the flu cough, sneeze, or talk, thereby disseminating droplets. These droplets can land in the mouths or noses of people who then inhale them into the lungs (CDC, 2022).
Symptoms of influenza are headache, fever, cough, sore throat, and aching muscles and joints. The influenza virus tends to cause more severe disease in infants, elderly people, young children, and those with a weakened immune system (WHO, 2023). The World Health Organization (WHO) estimates that approximately 5-10% of adults and 20-30% of children are affected by an influenza-like illness (ILI) annually (WHO, 2023).
Scope
- Seasonal Influenza (SI) vaccines Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of SI in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed incident cases of influenza- like illness (ILI), and lab-confirmed SI segmented by age (0-4 years, 5-17 years, 18-64 years, and ≥65 years) and sex. The report also includes a 10-year epidemiological forecast for the SI vaccinated population segmented by age (0-4 years, 5-17 years, 18-64 years, and ≥65 years).Seasonal Influenza (SI) vaccines Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of SI in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed incident cases of influenza- like illness (ILI), and lab-confirmed SI segmented by age (0-4 years, 5-17 years, 18-64 years, and ≥65 years) and sex. The report also includes a 10-year epidemiological forecast for the SI vaccinated population segmented by age (0-4 years, 5-17 years, 18-64 years, and ≥65 years).
Seasonal influneza vaccines epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SI vaccines markets.
- Quantify patient populations in the global SI markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SI therapeutics in each of the markets covered.
- About GlobalData
- 1 Heart Failure: Executive Summary
- 1.1 Catalyst
- 1.2 Related reports
- 1.3 Upcoming reports
- 2 Epidemiology
- 2.1 Disease background
- 2.2 Risk factors and comorbidities
- 2.3 Global and historical trends
- 2.4 7MM forecast methodology
- 2.4.1 Sources
- 2.4.2 Forecast assumptions and methods
- 2.4.3 Forecast assumptions and methods: diagnosed incident cases of HF - 7MM
- 2.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by EF
- 2.4.5 Forecast assumptions and methods: hospitalizations for acute HF
- 2.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation
- 2.4.7 Forecast assumptions and methods: hospital LoS days for acute HF hospitalizations
- 2.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization
- 2.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF - 7MM
- 2.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by EF
- 2.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by NYHA classes
- 2.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF-PEF (LVEF ≥50%) by NYHA class
- 2.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class
- 2.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF-REF (LVEF<40%) by NYHA class
- 2.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by ACCF/AHA stages
- 2.5 Epidemiological forecast for heart failure (2022-32)
- 2.5.1 Diagnosed incident cases of HF
- 2.5.2 Age-specific diagnosed incident cases of HF
- 2.5.3 Sex-specific diagnosed incident cases of HF
- 2.5.4 Diagnosed incident cases of HF by EF
- 2.5.5 Hospitalizations for acute HF
- 2.5.6 Acute HF hospitalizations based on presentation
- 2.5.7 Hospital LoS for acute HF
- 2.5.8 Re-admissions within 30 days post-discharge after acute HF
- 2.5.9 Diagnosed prevalent cases of HF
- 2.5.10 Age-specific diagnosed prevalent cases of HF
- 2.5.11 Sex-specific diagnosed prevalent cases of HF
- 2.5.12 Diagnosed prevalent cases of HF by EF
- 2.5.13 Diagnosed prevalent cases of HF by NYHA classes
- 2.5.14 Diagnosed prevalent cases of HF-PEF (LVEF ≥50%) by NYHA class
- 2.5.15 Diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class
- 2.5.16 Diagnosed prevalent cases of HF-REF (LVEF<40%) by NYHA class
- 2.5.17 Diagnosed prevalent cases of HF by ACCF/AHA stages
- 2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 COVID-19 impact
- 2.6.3 Limitations of the analysis
- 2.6.4 Strengths of the analysis
- 3 Appendix
- 3.1 Bibliography
- 3.2 About the Authors
- 3.2.1 Epidemiologist
- 3.2.2 Reviewers
- 3.2.3 Vice President of Disease Intelligence and Epidemiology
- Contact Us
- List of Tables
- Table 1: Summary of updated data types
- Table 2: Risk factors and comorbidities for SI
- List of Figures
- Figure 1: 7MM, diagnosed incident cases of lab-confirmed influenza, both sexes and all ages, N, 2022 and 2032
- Figure 2: 7MM, SI vaccinated cases, both sexes and all ages, N, 2022 and 2032
- Figure 3: 7MM, diagnosed incidence of lab-confirm
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook